105 related articles for article (PubMed ID: 32326511)
21. Prognostic Value of BRAF and KRAS Mutations in MSI and MSS Stage III Colon Cancer.
Taieb J; Le Malicot K; Shi Q; Penault-Llorca F; Bouché O; Tabernero J; Mini E; Goldberg RM; Folprecht G; Luc Van Laethem J; Sargent DJ; Alberts SR; Emile JF; Laurent Puig P; Sinicrope FA
J Natl Cancer Inst; 2017 May; 109(5):. PubMed ID: 28040692
[TBL] [Abstract][Full Text] [Related]
22. Irinotecan plus S-1 (IRIS) versus fluorouracil and folinic acid plus irinotecan (FOLFIRI) as second-line chemotherapy for metastatic colorectal cancer: a randomised phase 2/3 non-inferiority study (FIRIS study).
Muro K; Boku N; Shimada Y; Tsuji A; Sameshima S; Baba H; Satoh T; Denda T; Ina K; Nishina T; Yamaguchi K; Takiuchi H; Esaki T; Tokunaga S; Kuwano H; Komatsu Y; Watanabe M; Hyodo I; Morita S; Sugihara K
Lancet Oncol; 2010 Sep; 11(9):853-60. PubMed ID: 20708966
[TBL] [Abstract][Full Text] [Related]
23. Primary tumor location and survival in colorectal cancer: A retrospective cohort study.
Aggarwal H; Sheffield KM; Li L; Lenis D; Sorg R; Barzi A; Miksad R
World J Gastrointest Oncol; 2020 Apr; 12(4):405-423. PubMed ID: 32368319
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of CpG Island Methylator Phenotype as a Biomarker in Colorectal Cancer Treated With Adjuvant Oxaliplatin.
Cohen SA; Wu C; Yu M; Gourgioti G; Wirtz R; Raptou G; Gkakou C; Kotoula V; Pentheroudakis G; Papaxoinis G; Karavasilis V; Pectasides D; Kalogeras KT; Fountzilas G; Grady WM
Clin Colorectal Cancer; 2016 Jun; 15(2):164-9. PubMed ID: 26702772
[TBL] [Abstract][Full Text] [Related]
25. Impact of p53 expression and microsatellite instability on stage III colon cancer disease-free survival in patients treated by 5-fluorouracil and leucovorin with or without oxaliplatin.
Zaanan A; Cuilliere-Dartigues P; Guilloux A; Parc Y; Louvet C; de Gramont A; Tiret E; Dumont S; Gayet B; Validire P; Fléjou JF; Duval A; Praz F
Ann Oncol; 2010 Apr; 21(4):772-780. PubMed ID: 19833818
[TBL] [Abstract][Full Text] [Related]
26. Randomized phase II trial of TEGAFIRI (tegafur/uracil, oral leucovorin, irinotecan) compared with FOLFIRI (folinic acid, 5-fluorouracil, irinotecan) in patients with unresectable/recurrent colorectal cancer.
Shigeta K; Hasegawa H; Okabayashi K; Tsuruta M; Ishii Y; Endo T; Ochiai H; Kondo T; Kitagawa Y
Int J Cancer; 2016 Aug; 139(4):946-54. PubMed ID: 27061810
[TBL] [Abstract][Full Text] [Related]
27. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial.
Taieb J; Tabernero J; Mini E; Subtil F; Folprecht G; Van Laethem JL; Thaler J; Bridgewater J; Petersen LN; Blons H; Collette L; Van Cutsem E; Rougier P; Salazar R; Bedenne L; Emile JF; Laurent-Puig P; Lepage C;
Lancet Oncol; 2014 Jul; 15(8):862-73. PubMed ID: 24928083
[TBL] [Abstract][Full Text] [Related]
28. Prognostic value of mucinous histology depends on microsatellite instability status in patients with stage III colon cancer treated with adjuvant FOLFOX chemotherapy: a retrospective cohort study.
Kim SH; Shin SJ; Lee KY; Kim H; Kim TI; Kang DR; Hur H; Min BS; Kim NK; Chung HC; Roh JK; Ahn JB
Ann Surg Oncol; 2013 Oct; 20(11):3407-13. PubMed ID: 23943026
[TBL] [Abstract][Full Text] [Related]
29. Clinical effects of adjuvant active specific immunotherapy differ between patients with microsatellite-stable and microsatellite-instable colon cancer.
de Weger VA; Turksma AW; Voorham QJ; Euler Z; Bril H; van den Eertwegh AJ; Bloemena E; Pinedo HM; Vermorken JB; van Tinteren H; Meijer GA; Hooijberg E
Clin Cancer Res; 2012 Feb; 18(3):882-9. PubMed ID: 22156611
[TBL] [Abstract][Full Text] [Related]
30. FOLFOX and FOLFIRI Use in Stage IV Colon Cancer: Analysis of SEER-Medicare Data.
Neugut AI; Lin A; Raab GT; Hillyer GC; Keller D; O'Neil DS; Accordino MK; Kiran RP; Wright J; Hershman DL
Clin Colorectal Cancer; 2019 Jun; 18(2):133-140. PubMed ID: 30878317
[TBL] [Abstract][Full Text] [Related]
31. Single Patient Classifier Assay, Microsatellite Instability, and Epstein-Barr Virus Status Predict Clinical Outcomes in Stage II/III Gastric Cancer: Results from CLASSIC Trial.
Roh CK; Choi YY; Choi S; Seo WJ; Cho M; Jang E; Son T; Kim HI; Kim H; Hyung WJ; Huh YM; Noh SH; Cheong JH
Yonsei Med J; 2019 Feb; 60(2):132-139. PubMed ID: 30666834
[TBL] [Abstract][Full Text] [Related]
32. [Evaluation value of preoperative peripheral blood lymphocyte-to-monocyte ratio on the prognosis of patients with stage III colon cancer].
Chen J; Peng J; Fan W; Zhang R; Wang F; Zhou W; Xu D; Pan Z; Lu Z
Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jan; 22(1):73-78. PubMed ID: 30703797
[TBL] [Abstract][Full Text] [Related]
33. Change in Topoisomerase 1-Positive Circulating Tumor Cells Affects Overall Survival in Patients with Advanced Breast Cancer after Treatment with Etirinotecan Pegol.
Rugo HS; Cortes J; Awada A; O'Shaughnessy J; Twelves C; Im SA; Hannah A; Lu L; Sy S; Caygill K; Zajchowski DA; Davis DW; Tagliaferri M; Hoch U; Perez EA
Clin Cancer Res; 2018 Jul; 24(14):3348-3357. PubMed ID: 29618616
[No Abstract] [Full Text] [Related]
34. A systematic overview of chemotherapy effects in colorectal cancer.
Ragnhammar P; Hafström L; Nygren P; Glimelius B;
Acta Oncol; 2001; 40(2-3):282-308. PubMed ID: 11441937
[TBL] [Abstract][Full Text] [Related]
35. Prognostic and predictive roles of high-degree microsatellite instability in colon cancer: a National Cancer Institute-National Surgical Adjuvant Breast and Bowel Project Collaborative Study.
Kim GP; Colangelo LH; Wieand HS; Paik S; Kirsch IR; Wolmark N; Allegra CJ;
J Clin Oncol; 2007 Mar; 25(7):767-72. PubMed ID: 17228023
[TBL] [Abstract][Full Text] [Related]
36. Fluorouracil, leucovorin, and irinotecan plus either sunitinib or placebo in metastatic colorectal cancer: a randomized, phase III trial.
Carrato A; Swieboda-Sadlej A; Staszewska-Skurczynska M; Lim R; Roman L; Shparyk Y; Bondarenko I; Jonker DJ; Sun Y; De la Cruz JA; Williams JA; Korytowsky B; Christensen JG; Lin X; Tursi JM; Lechuga MJ; Van Cutsem E
J Clin Oncol; 2013 Apr; 31(10):1341-7. PubMed ID: 23358972
[TBL] [Abstract][Full Text] [Related]
37. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study.
André T; de Gramont A; Vernerey D; Chibaudel B; Bonnetain F; Tijeras-Raballand A; Scriva A; Hickish T; Tabernero J; Van Laethem JL; Banzi M; Maartense E; Shmueli E; Carlsson GU; Scheithauer W; Papamichael D; Möehler M; Landolfi S; Demetter P; Colote S; Tournigand C; Louvet C; Duval A; Fléjou JF; de Gramont A
J Clin Oncol; 2015 Dec; 33(35):4176-87. PubMed ID: 26527776
[TBL] [Abstract][Full Text] [Related]
38. A randomized phase II trial of pemetrexed plus irinotecan (ALIRI) versus leucovorin-modulated 5-FU plus irinotecan (FOLFIRI) in first-line treatment of locally advanced or metastatic colorectal cancer.
Underhill C; Goldstein D; Gorbounova VA; Biakhov MY; Bazin IS; Granov DA; Hossain AM; Blatter J; Kaiser C; Ma D
Oncology; 2007; 73(1-2):9-20. PubMed ID: 18334829
[TBL] [Abstract][Full Text] [Related]
39. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest.
Falcone A; Ricci S; Brunetti I; Pfanner E; Allegrini G; Barbara C; Crinò L; Benedetti G; Evangelista W; Fanchini L; Cortesi E; Picone V; Vitello S; Chiara S; Granetto C; Porcile G; Fioretto L; Orlandini C; Andreuccetti M; Masi G;
J Clin Oncol; 2007 May; 25(13):1670-6. PubMed ID: 17470860
[TBL] [Abstract][Full Text] [Related]
40. [Predictive and prognostic value of MSI phenotype in adjuvant colon cancer: Who and how to treat?].
Zaanan A; Taieb J
Bull Cancer; 2019 Feb; 106(2):129-136. PubMed ID: 30527814
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]